U.S. markets close in 3 hours 44 minutes
  • S&P 500

    4,149.95
    -38.48 (-0.92%)
     
  • Dow 30

    34,261.80
    -481.02 (-1.38%)
     
  • Nasdaq

    13,366.83
    -35.02 (-0.26%)
     
  • Russell 2000

    2,200.82
    -11.88 (-0.54%)
     
  • Crude Oil

    64.92
    0.00 (0.00%)
     
  • Gold

    1,835.60
    -2.00 (-0.11%)
     
  • Silver

    27.67
    +0.17 (+0.63%)
     
  • EUR/USD

    1.2174
    +0.0040 (+0.33%)
     
  • 10-Yr Bond

    1.6200
    +0.0180 (+1.12%)
     
  • GBP/USD

    1.4153
    +0.0032 (+0.22%)
     
  • USD/JPY

    108.5500
    -0.2910 (-0.27%)
     
  • BTC-USD

    56,119.58
    -2,191.80 (-3.76%)
     
  • CMC Crypto 200

    1,503.89
    +1,261.21 (+519.70%)
     
  • FTSE 100

    6,947.99
    -175.69 (-2.47%)
     
  • Nikkei 225

    28,608.59
    -909.71 (-3.08%)
     

Endo Health's Aveed testosterone injection approved by FDA

Endo's operating company Endo Pharmaceuticals received FDA approval of Aveed, testosterone undecanoate, injection for the treatment of adult men with a deficiency or absence of the male hormone testosterone. Aveed is a new prescription medicine indicated to produce serum testosterone levels in the normal range by administration of a single 3-mL intramuscular injection. It is expected to be available in early March.